Scienture Holdings, Inc. (SCNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($66.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Scienture Holdings, Inc. (SCNX) financial flexibility to assess the company's free cash flow relative to its total liabilities.
Scienture Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see SCNX company net worth for the company's overall valuation and market capitalisation.
Scienture Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scienture Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Draper Esprit PLC
LSE:GROW
|
0.024x |
|
Onelife Capital Advisors Limited
NSE:ONELIFECAP
|
-0.221x |
|
Steel City Securities Limited
NSE:STEELCITY
|
0.025x |
|
Malpac Holdings Bhd
KLSE:4936
|
0.000x |
|
Biotechnology Assets S.A.
MC:BST
|
0.102x |
|
Saray Matbaacilik Kagitcilik Kirtasiyecilik Ticaret ve Sanayi AS
IS:SAMAT
|
-0.082x |
|
Dolphin Entertainment Inc
NASDAQ:DLPN
|
0.060x |
|
Fourth-Link Inc.
KQ:056730
|
0.000x |
Annual Cash Flow Conversion Efficiency for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scienture Holdings, Inc. from 2006 to 2025. View latest Scienture Holdings, Inc. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.12 Million | $-13.38 Billion | -190.850x | -105688.08% |
| 2024-12-31 | $79.07 Million | $-14.27 Million | -0.180x | +95.60% |
| 2023-12-31 | $542.35K | $-2.23 Million | -4.103x | +10.09% |
| 2022-12-31 | $342.87K | $-1.56 Million | -4.563x | -570.44% |
| 2021-12-31 | $3.77 Million | $-2.57 Million | -0.681x | -166.73% |
| 2020-12-31 | $8.68 Million | $-2.21 Million | -0.255x | -845.21% |
| 2019-12-31 | $4.14 Million | $141.78K | 0.034x | -89.42% |
| 2018-12-31 | $844.67K | $273.39K | 0.324x | +158.81% |
| 2017-12-31 | $-311.93K | $171.67K | -0.550x | -148.11% |
| 2016-12-31 | $-1.15 Million | $-1.31 Million | 1.144x | +115.48% |
| 2015-12-31 | $267.02K | $-1.97 Million | -7.392x | -364.14% |
| 2014-12-31 | $668.44K | $-1.06 Million | -1.593x | +75.32% |
| 2013-12-31 | $130.87K | $-844.58K | -6.454x | -1100255.67% |
| 2008-12-31 | $-48.01 Million | $-28.16K | 0.001x | -99.93% |
| 2007-12-31 | $-18.51K | $-16.07K | 0.868x | +234.87% |
| 2006-12-31 | $9.67K | $-6.22K | -0.644x | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more